Company intelligence / Profile preview

宝瑩

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Bao Pharmaceuticals is a pioneer in China leveraging synthetic biology to develop recombinant biologic drugs that address significant unmet medical needs. Their lead product KJ017 is a recombinant human hyaluronidase enabling large-volume subcutaneous delivery of therapeutics. The company has five clinical-stage candidates and seven preclinical assets across four strategic therapeutic areas. No pivotal or late-phase trial results are publicly disclosed as of January 2025

Therapeutic areas: OtherMetabolic DisordersImmunologyWomen's Health
Modalities: Recombinant proteinMonoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on 宝瑩.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 宝瑩.

Explore the full profile